However, the Secretary's duty to provide or ensure the provision of services for health service purposes has been removed and replaced by a duty to 'promote' the NHS:. a) performance of public health functions; and. The Secretary of State must perform his duties with a view to ensuring continuous improvement in the quality of services provided to the individuals concerned. a) prevention, diagnosis or treatment of disease or (b) protection or improvement of public health.
Administration of the NHS
Before the beginning of each financial year, the Secretary of State must publish and submit to Parliament a document called the "mandate". Answer: Five main bodies are responsible for the overall governance of the NHS - DH, NHS CB, NICE, CQC and Monitor.
NHS Pharmaceutical Services in the Community
Enhanced services are commissioned by the local NHS CB in response to the needs of the local population. A scheduled drug that is a drug with an appropriate nonproprietary name may be provided in response to an order on a prescription form or repeatable prescription for a drug (a "prescribed drug") that is not a scheduled drug but has the same non-proprietary name as a listed drug if: . a) the prescribed medicine is classified by this non-proprietary name or its formula;
The Drug Tariff
Under Regulation 11 of the NHS (Pharmaceutical and Community Pharmaceutical Services) Regulations 2013, the DT lists of drugs and devices are incorporated into the Terms of Service (TOS). The DT sets out much of the prescribing and dispensing arrangement for NHS patients.
CATEGORIES
The 'Blacklist' is found in Schedule 1 of the NHS (GMS Contracts) (Prescribing Drugs etc) Regulations 2004 which is reproduced in Part XVIIIA of the DT. The 'Selected List' is found in Schedule 2 of the NHS (GMS Contracts) (Prescribing Drugs etc) Regulations 2004 which is reproduced in Part XVIIIB of the DT.
Applications to Dispense NHS Scripts
The test is set out in s129 of the NHS Act 2006 (as amended) and details of how this is to work can be found in the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013SI No. The detailed information that must be included in the PNA is set out in Schedule 1 of the 2012 Regulations:. Each application must contain the information set out in Schedule 2 of the 2013 Regulations.
This is based on the complexity of the application, previous applications in the area and any appeals, particularly well-founded appeals, to the FHSAU about this. The detailed information that must be included in the PNA is set out in Schedule 1 of the 2013 Regulations.
Rural Dispensing
A reserved location is an area within a controlled locality where the total of all patient lists for the area within a radius of 1.6 km (1 mile) of the premises or proposed location is less than 2750. Under Regulation 41(3) of Regulations 2013 an area within a 1.6km radius of a relevant location is a 'reserved location' if:. a) the number of individuals residing in that area who are on the patient list (which may be a total number of patients on more than one patient list) is less than 2750; and. There is no appeal procedure from a Board decision that the patient does not have any serious difficulties.
Former PCTs had to delineate the boundaries of controlled areas on a map. A reserved location is an area within a controlled locality where the total number of all patient lists for the area within a 1.6 km (1 mile) radius of the proposed premises or location is less than 2,750.
Prescription Charges
Only one charge must be paid for the delivery of two or more devices of the same type (excluding elastic stockings). The delivery of two or more parts of the same device also assumes only one charge. Guidance on extending the list of medical conditions has been issued by the NHS Business Services Authority (BSA).
Although the policy states "in person," it also applies when a nurse is acting on behalf of a physician. Although the policy states "in person," this exception also applies when a nurse is acting on behalf of a physician.
The Interests of the Public
The Health and Well-Being Board is expected to be formally established when the relevant provisions in the Act on Health and Social Care come into force from April 2013. Regulated activities are listed in Schedule 1 of the Act on Health and Social Care 2008 (Regulated Activities) 2010. Monitor is a non-departmental public body established under the Health and Social Care (Community Health and Standards) Act 2003.
The Health and Social Care Act 2012 changes the way NHS service providers will be regulated. CCGs are required to consult the views of the Health and Wellbeing Board throughout the commissioning process to ensure that commissioning plans follow the joint health and wellbeing strategy.
Complaints and Breaches of the Terms of Service
Upon confirmation of the complaint, the pharmacy must offer the complainant an interview at the agreed time: a) method of handling the complaint; and (b) the period (the “Response Period”) during which:. i) the investigation of the complaint is likely to be completed; and (ii) the response is likely to be sent to the complainant. This regulation applies to a complaint made on or after April 1, 2009 under these regulations for:. i) performing its functions; or ii) the performance of any function which it performs or will perform in accordance with the arrangements between it and the local authority under section 75 of the Act 2006 relating to the performance of health-related functions of the local authority;. Each withholding is subject to the following:. a) CB NHS is convinced that the violation is or was without reasonable cause;
The NHS CB may remove a contractor from the pharmaceutical list if the contractor: a) fails to take the steps set out in a remediation notice and the Board is satisfied that it is necessary to remove the contractor from the pharmaceutical list, or to delist certain listed pharmacy premises: i) to protect the safety of all persons to whom the Contractor may provide pharmaceutical services; or. ii) to protect the NHS CB against material financial loss; or (b) has violated the Terms of Service, and:. i) the contractor has received repeated notices of remediation or infringement; ii) has previously received a cure notice or breach notice and the Board of Directors is satisfied that the contractor is likely to continue violating the Terms of Service without good reason. The NHS CB may only remove the contractor, or the pharmacies listed in relation to that contractor, from the pharmaceutical list under paragraph (1) if: (a) the removal is justified and proportionate having regard to the nature and seriousness of the infringements (or likely infringements) and the reasons therefor; And.
Retail Pharmacy
One of the partners who is a pharmacist or another pharmacist must be. responsible pharmacist' in these premises. The responsible pharmacist must be: (a) the Superintendent mentioned in subsection (1)(a) of this section, or (b) a pharmacist subject to the directions of the Superintendent. A 'responsible pharmacist' must manage the part of the business in the premises that relates to:. a) the retail sale on those premises of medicinal products (whether or not on a general sales list), and.
A notice must be conspicuously displayed at that premises stating:. a) the name of the responsible pharmacist for the time being. One of the partners who is a pharmacist or another pharmacist must be the 'pharmacist in charge' at that premises.
The Manufacture and Licensing of Medicinal Products
In practice, the licensing of medicinal products for human use is regulated by the Ministry of Health's MHRA. If the results are satisfactory, the data (which will consist of thousands of pages) will be submitted to the MHRA, who will pass the evidence on to an advisory committee - the Commission for Human Medicines (CHM). Definition of medicinal product in Article 1 of Directive 2001/83/. The new definition states that a drug is:
Other information includes dosage, route and route of administration, shelf life, storage precautions, and the results of clinical studies and tests. the summary of product characteristics in relation to a medicinal product means: (a) if the product has a UK marketing authorization or traditional herbal registration, the summary of product characteristics: (i) as approved by the licensing authority when granting the authorization or registration, or. (ii) where the summary has been modified since that approval, as amended; or (b) if the product has been granted an EU marketing authorization, the summary of product characteristics: (i) as approved by the European Commission when the authorization was granted, or (ii) if the summary has been amended since that approval, as so amended; In practice, licensing of medicines for human use is handled by the MHRA of the Department of Health.
Control on Sales of Medicines
Regulation 214 of the Medicines for Human Use Regulations requires that a person must not sell or supply POM unless in accordance with a prescription from a licensed practitioner. A prescription for POMs must meet the conditions laid down in Regulation 217 of the Medicines for Human Use Regulations. The booking must be made on the day of the transaction, or on the following day.
The record must contain the details set out in Schedule 23 of the Human Medicines Regulations. Make a record (which must be available on the pharmacy premises) of the pharmacist in charge of the pharmacy on any date and at any time – Section 72A(4).
Emergency Supplies, Deliveries and Faxed Prescriptions
Emergency supplies, deliveries and faxed prescriptions. a) the pharmacist must be convinced that the sale or supply has been requested by a prescriber who, due to emergency reasons, is unable to immediately issue a prescription. Regulation 221 normally imposes conditions on the sale of General Sales List (GSL) products so that:. a) the supply is made only from premises which can be "closed to exclude the public". The Society acknowledges that in some 'secure environments' the use of faxed prescriptions has become routine.
The POM is sold or supplied in accordance with the directions of the requesting prescriber. POM is not a controlled drug in schedule 1, 2 or 3 of the Misuse of Drugs Regulations 1985.
Unlicensed Products
Medicines and Healthcare Products Regulatory Agency (MHRA) Guidance Note No. 14 "Supply of relevant unlicensed medicinal products to individual patients" shows how in practice the MHRA will determine whether an activity is "preparation" or "production". Several recent studies have shown that many physicians are unaware of the limitations for use stated in the data sheets for a product, and they may be grateful for a reminder. In such cases, the competent authority of the Member State must inform the marketing authorization holder where the medicinal product in question is authorised.
The Member State must ensure that the following requirements are met: labeling and package leaflet. the classification of the drug. The publicly accessible register of medicinal products authorized under Article 126a shall be available on the Commission's website.4.
